Cara Cassino
Keine laufenden Positionen mehr
Vermögen: - $ am 31.05.2024
Karriereverlauf von Cara Cassino
Ehemalige bekannte Positionen von Cara Cassino
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CONTRAFECT CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 25.09.2015 | 14.08.2022 |
FOREST LABORATORIES, INC. | Corporate Officer/Principal | 01.12.2014 | 01.09.2015 |
PFIZER, INC. | Corporate Officer/Principal | 01.01.2008 | 01.01.2013 |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 | 01.01.2007 |
New York University School of Medicine | Corporate Officer/Principal | - | - |
Ausbildung von Cara Cassino
NYU College of Dentistry | Undergraduate Degree |
New York University School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CONTRAFECT CORPORATION | Health Technology |
PFIZER, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Forest Laboratories, Inc.
Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
- Börse
- Insiders
- Cara Cassino
- Erfahrung